Literature DB >> 30365357

Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.

Ilse Gantois1,2, Jelena Popic1,2, Arkady Khoutorsky3, Nahum Sonenberg1,2.   

Abstract

Fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability and autism spectrum disorder. Loss of the fragile X mental retardation protein, FMRP, engenders molecular, behavioral, and cognitive deficits in FXS patients. Experiments using different animal models advanced our knowledge of the pathophysiology of FXS and led to the discovery of many targets for drug treatments. In this review, we discuss the potential of metformin, an antidiabetic drug approved by the US Food and Drug Administration, to correct core symptoms of FXS and other neurological disorders in humans. We summarize its mechanisms of action in different animal and cellular models and human diseases.

Entities:  

Keywords:  ERK; autism spectrum disorders; fragile X syndrome; mTOR; metformin; protein synthesis

Mesh:

Substances:

Year:  2018        PMID: 30365357     DOI: 10.1146/annurev-med-081117-041238

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  22 in total

1.  Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay.

Authors:  Tatsuaki Kurosaki; Naoto Imamachi; Christoph Pröschel; Shuhei Mitsutomi; Rina Nagao; Nobuyoshi Akimitsu; Lynne E Maquat
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

2.  Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice.

Authors:  Craige C Wrenn; Eric French; Dustin Baker; Randall McCallian; Ryan Kirk; Mark P Reilly; Maria G Valdovinos
Journal:  Psychopharmacology (Berl)       Date:  2021-01-15       Impact factor: 4.530

Review 3.  The molecular biology of FMRP: new insights into fragile X syndrome.

Authors:  Joel D Richter; Xinyu Zhao
Journal:  Nat Rev Neurosci       Date:  2021-02-19       Impact factor: 38.755

4.  Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases.

Authors:  Dragana Protic; Elber Y Aydin; Flora Tassone; Maria M Tan; Randi J Hagerman; Andrea Schneider
Journal:  Mol Genet Genomic Med       Date:  2019-05-18       Impact factor: 2.183

Review 5.  Metformin: the updated protective property in kidney disease.

Authors:  Qingjun Pan; Xing Lu; Chunfei Zhao; Shuzhen Liao; Xiaoqun Chen; Fengbiao Guo; Chen Yang; Hua-Feng Liu
Journal:  Aging (Albany NY)       Date:  2020-05-01       Impact factor: 5.682

Review 6.  New Targeted Treatments for Fragile X Syndrome.

Authors:  Dragana Protic; Maria J Salcedo-Arellano; Jeanne Barbara Dy; Laura A Potter; Randi J Hagerman
Journal:  Curr Pediatr Rev       Date:  2019

Review 7.  Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments.

Authors:  Maria Jimena Salcedo-Arellano; Ana Maria Cabal-Herrera; Ruchi Harendra Punatar; Courtney Jessica Clark; Christopher Allen Romney; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2020-11-19       Impact factor: 7.620

8.  Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment.

Authors:  Kagistia Hana Utami; Nur Amirah Binte Mohammad Yusof; Jing Eugene Kwa; Ulla-Kaisa Peteri; Maija L Castrén; Mahmoud A Pouladi
Journal:  Mol Autism       Date:  2020-05-27       Impact factor: 7.509

Review 9.  Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection.

Authors:  Bor Luen Tang
Journal:  Brain Sci       Date:  2019-09-18

10.  Metformin treatment in young children with fragile X syndrome.

Authors:  Hazel Maridith B Biag; Laura A Potter; Victoria Wilkins; Sumra Afzal; Alexis Rosvall; Maria Jimena Salcedo-Arellano; Akash Rajaratnam; Ramiro Manzano-Nunez; Andrea Schneider; Flora Tassone; Susan M Rivera; Randi J Hagerman
Journal:  Mol Genet Genomic Med       Date:  2019-09-14       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.